A simplified protocol employing elacridar in rodents: A screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier

Drug Metabolism Letters

Volumn 6, Issue 2, 2012, Pages 134-144

  Kallem, Rajareddy ^a   Kulkarni, Chetan P ^a   Patel, Dakshay ^a,d   Thakur, Megha ^a   Sinz, Michael ^b   Singh, Sheelendra P ^a   Mahammad, S Shahe ^a   Mandlekar, Sandhya ^c  

^a SYNGENE INTERNATIONAL LTD   (India)

^b BRISTOL MYERS SQUIBB   (United States)

^c Bristol Myers Squibb India Ltd   (India)

^d Custom Biologics   (Canada)

Author keywords

Blood brain barrier; Brain to plasma ratio; Digoxin; Elacridar; P glycoprotein; Pharmacokinetics; Quinidine

Indexed keywords

DIGOXIN; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; TALINOLOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SCREENING; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ACRIDINES; ANIMALS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, LIQUID; COST-BENEFIT ANALYSIS; DIGOXIN; DRUG DESIGN; DRUG INTERACTIONS; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; MICE; P-GLYCOPROTEIN; PROPANOLAMINES; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; TETRAHYDROISOQUINOLINES; TIME FACTORS; TISSUE DISTRIBUTION;

MUS; RATTUS; RODENTIA;

EID: 84876741564     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231212804096682     Document Type: Article

References (39)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P.J. Ex-perimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26.
2. Fricker, G.; Miller, D. S. Modulation of drug transporters at the blood-brain barrier. Pharmacology 2004, 70, 169-176.
3. Pardridge, W. M. Molecular Trojan horses for blood-brain barrier drug delivery. Curr. Opin. Pharmacol., 2006, 6, 494-500.
4. Miller, D. S.; Bauer, B.; Hartz, A. M. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol. Rev., 2008, 60, 196-209.
5. Agarwal, S.; Uchida, Y.; Mittapalli, R. K.; Sane, R.; Terasaki, T.; Elmquist, W. F. Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-Glycoprotein (P-gp), Breast Cancer Resistance Protein (Bcrp), and P-gp/Bcrp Knockout Mice. Drug Metab. Dispos., 2012, 40, 1164-1169.
6. Tsuji, A.; Terasaki, T.; Takabatake, Y.; Tenda, Y.; Tamai, I.; Ya-mashima, T.; Moritani, S.; Tsuruo, T.; Yamashita, J. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci., 1992, 51, 1427-1437.
7. Schinkel, A. H.; Smit, J. J.; van Tellingen, O.; Beijnen, J. H.; Wa-genaar, E.; van Deemter, L.; Mol, C. A.; van der Valk, M. A.; Ro-banus-Maandag, E. C.; te Riele, H. P.; et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77, 491-502.
8. Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; Borst, P. Absence of the mdr1a P-Glycoprotein in mice affects tissue dis-tribution and pharmacokinetics of dexamethasone, digoxin, and cy-closporin A. J. Clin. Invest., 1995, 96, 1698-1705.
9. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acri-donecarboxamide derivative. Cancer Res., 1993, 53, 4595-4602.
10. Wallstab, A.; Koester, M.; Bohme, M.; Keppler, D. Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acri-done carboxamide derivative GG918. Br. J. Cancer, 1999, 79, 1053-60.
11. Evers, R.; Kool, M.; Smith, A. J.; van Deemter, L.; de Haas, M.; Borst, P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1-and MRP2-mediated transport. Br. J. Cancer, 2000, 83, 366-374.
12. Jonker, J. W.; Smit, J. W.; Brinkhuis, R. F. Maliepaard, M.; Bei-jnen, J. H.; Schellens, J. H.; Schinkel, A. H.: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 2000, 92, 1651-1656.
13. Litman, T.; Brangi, M.; Hudson, E.; Fetsch, P.; Abati, A.; Ross, D. D.; Miyake, K.; Resau, J. H.; Bates, S. E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci., 2000, 113 (Pt 11), 2011-2021.
14. de Vries, N. A.; Zhao, J.; Kroon, E.; Buckle, T.; Beijnen, J. H.; van Tellingen, O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res., 2007, 13, 6440-6449.
15. Polli, J. W.; Humphreys, J. E.; Harmon, K. A.; Castellino, S.; O'Mara, M. J.; Olson, K. L.; John-Williams, L. S.; Koch, K. M.; Serabjit-Singh, C. J. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl) ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, la-patinib) disposition and drug interactions. Drug Metab. Dispos., 2008, 36, 695-701.
16. Chen, Y.; Agarwal, S.; Shaik, N. M.; Chen, C.; Yang, Z.; Elmquist, W. F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther., 2009, 330, 956-963.
17. Agarwal, S.; Sane, R.; Ohlfest, J. R.; Elmquist, W. F. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther., 2011, 336, 223-233.
18. Lee, Y. J.; Kusuhara, H.; Jonker, J. W.; Schinkel, A. H.; Sugiyama, Y. Investigation of efflux transport of dehydroepiandrosterone sul-fate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J. Pharmacol. Exp. Ther., 2005, 312, 44-52.
19. Zhao, R.; Raub, T. J.; Sawada, G. A.; Kasper, S. C.; Bacon, J. A.; Bridges, A. S.; Pollack, G. M. Breast cancer resistance protein in-teracts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier. Drug Metab. Dispos., 2009, 37, 1251-1258.
20. Lagas, J. S.; van Waterschoot, R. A.; van Tilburg, V. A.; Hille-brand, M. J.; Lankheet, N.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res., 2009, 15, 2344-2351.
21. Kawahara, M.; Sakata, A.; Miyashita, T.; Tamai, I.; Tsuji, A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci., 1999, 88, 1281-1287.
22. Bihorel, S.; Camenisch, G.; Lemaire, M.; Scherrmann, J. M. Modu-lation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res., 2007, 24, 1720-1728.
23. Sugimoto, H.; Hirabayashi, H.; Kimura, Y.; Furuta, A.; Amano, N.; Moriwaki, T. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats. Drug Metab. Dispos., 2011, 39, 8-14.
24. Liu, X.; Van Natta, K.; Yeo, H.; Vilenski, O.; Weller, P. E.; Wor-boys, P. D.; Monshouwer, M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab. Dispos., 2009, 37, 787-793.
25. Collett, A.; Tanianis-Hughes, J.; Hallifax, D.; Warhurst, G. Predict-ing P-glycoprotein effects on oral absorption: correlation of trans-port in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm. Res., 2004, 21, 819-826.
26. Shingaki, T.; Hidalgo, I. J.; Furubayashi, T.; Sakane, T.; Katsumi, H.; Yamamoto, A.; Yamashita, S. Nasal delivery of P-gp substrates to the brain through the nose-brain pathway. Drug Metab. Pharma-cokinet., 2011, 26, 248-255.
27. Mayer, U.; Wagenaar, E.; Dorobek, B.; Beijnen, J. H.; Borst, P.; Schinkel, A. H. Full blockade of intestinal P-glycoprotein and ex-tensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest., 1997, 100, 2430-2436.
28. Kusuhara, H.; Suzuki, H.; Terasaki, T.; Kakee, A.; Lemaire, M.; Sugiyama, Y. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J. Pharmacol. Exp. Ther., 1997, 283, 574-580.
29. Trausch, B.; Oertel, R.; Richter, K.; Gramatte, T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm. Drug Dispos., 1995, 16, 403-414.
30. Xiao, G.; Black, C.; Hetu, G.; Sands, E.; Wang, J.; Caputo, R.; Rohde, E.; Gan, L. S. Cerebrospinal fluid can be used as a surro-gate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab. Dispos., 2012, 40, 779-787.
31. Batrakova, E. V.; Miller, D. W.; Li, S.; Alakhov, V. Y.; Kabanov, A. V.; Elmquist, W. F. Pluronic P85 enhances the delivery of di-goxin to the brain: in vitro and in vivo studies. J. Pharmacol. Exp. Ther., 2001, 296, 551-557.
32. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E.; Kasman, I. N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos., 2005, 33, 165-174.
33. Murakami, H.; Takanaga, H.; Matsuo, H.; Ohtani, H.; Sawada, Y. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am. J. Physiol. Heart Circ. Physiol., 2000, 279, 1022-28.
34. Cutler, L.; Howes, C.; Deeks, N. J.; Buck, T. L.; Jeffrey, P. Devel-opment of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J. Pharm. Sci., 2006, 95, 1944-1953.
35. Kagan, L.; Dreifinger, T.; Mager, D. E.; Hoffman, A. Role of p-glycoprotein in region-specific gastrointestinal absorption of tali-nolol in rats. Drug Metab. Dispos., 2010, 38, 1560-1566.
36. Ward, K. W.; Azzarano, L. M. Preclinical pharmacokinetic proper-ties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9, 10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-isoquino linyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. J. Pharmacol. Exp. Ther., 2004, 310, 703-709.
37. Kuntner, C.; Bankstahl, J. P.; Bankstahl, M.; Stanek, J.; Wanek, T.; Stundner, G.; Karch, R.; Brauner, R.; Meier, M.; Ding, X.; Muller, M.; Loscher, W.; Langer, O. Dose-response assessment of tariqui-dar and elacridar and regional quantification of P-glycoprotein in-hibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 942-953.
38. de Vries, N. A.; Zhao, J.; Kroon, E.; Buckle, T.; Beijnen, J. H.; van Tellingen, O. P-glycoprotein and breast cancer resistance pro-tein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res., 2007, 13, 6440-6449.
39. Liu, X.; Ding, X.; Deshmukh, G.; Liederer, B. M.; Hop, C. E. Use of the cassette-dosing approach to assess brain penetration in drug discovery. Drug Metab. Dispos., 2012, 40, 963-969.